or Try an Advanced Search...

    Technical Analysis for GNTA - Genenta Science S.p.A.

    Grade Last Price % Change Price Change
    D 3.70 0.82% 0.03
    GNTA closed up 0.82 percent on Wednesday, May 8, 2024, on 16 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical GNTA trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Weak + Overbought Other 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Up 5 Days in a Row Strength 0.00%
    Gapped Down Weakness 0.00%
    Older End-of-Day Signals for GNTA ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 9 hours ago
    Gap Down Partially Closed about 12 hours ago
    Gap Down Closed about 12 hours ago
    Reversed from Down about 12 hours ago
    50 DMA Support about 12 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GNTA Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Cell Biology Gene Therapy Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme

    Is GNTA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 4 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Feb 8 Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
    Nov 14 Individual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%
    See more GNTA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.8099
    52 Week Low 2.2
    Average Volume 5,998
    200-Day Moving Average 4.73
    50-Day Moving Average 3.66
    20-Day Moving Average 3.36
    10-Day Moving Average 3.25
    Average True Range 0.38
    RSI (14) 55.36
    ADX 26.47
    +DI 19.41
    -DI 29.93
    Chandelier Exit (Long, 3 ATRs) 2.84
    Chandelier Exit (Short, 3 ATRs) 3.33
    Upper Bollinger Bands 4.15
    Lower Bollinger Band 2.57
    Percent B (%b) 0.71
    BandWidth 47.06
    MACD Line -0.03
    MACD Signal Line -0.11
    MACD Histogram 0.0807
    Fundamentals Value
    Market Cap 67.4 Million
    Num Shares 18.2 Million
    EPS -0.78
    Price-to-Earnings (P/E) Ratio -4.74
    Price-to-Sales 0.00
    Price-to-Book 2.22
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.06
    Resistance 3 (R3) 4.05 3.93 4.00
    Resistance 2 (R2) 3.93 3.83 3.93 3.98
    Resistance 1 (R1) 3.81 3.78 3.87 3.82 3.96
    Pivot Point 3.69 3.69 3.72 3.69 3.69
    Support 1 (S1) 3.57 3.59 3.63 3.58 3.44
    Support 2 (S2) 3.45 3.54 3.45 3.42
    Support 3 (S3) 3.33 3.45 3.40
    Support 4 (S4) 3.34